The Afraxis High Content Analysis technology platform provides a number of opportunities for potential partners. Please contact us directly to discuss these alternatives.

Research and Development

Partners can evaluate their compounds in our high content analysis platform to determine a compound’s effect on dendritic spine morphology and synapse function. Combined with animal efficacy studies, ESP technology enables our partners to prioritize compounds for clinical development with an increased likelihood of exhibiting efficacy in human trials.


Our partners can evaluate development or clinical stage compounds whose advancement have been discontinued in our high content analysis platform to explore the potential to reposition those compounds into alternative CNS indications.

Assess adverse cognitive impact

Our partners can evaluate non-CNS development or clinical stage compounds to assess the risk that the compound is active in the brain and imposes negative cognitive side effects.